Vertex Pharmaceuticals is expected to report consensus revenue of $3.25 billion and EPS of $3.67, with the current stock price of $448.20 trading below the average analyst price target of $515.00. Investors are primarily focused on the commercial launch trajectory and patient uptake of Casgevy, the company's pioneering CRISPR-based gene therapy.
Growth is supported by the continued dominance of the Trikafta franchise in cystic fibrosis and recent regulatory progress for suzetrigine in acute pain. Analysts are looking for evidence that Vertex can successfully diversify its revenue stream beyond its core pulmonary portfolio as it transitions into a multi-product commercial stage company.